We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Essilorluxottica | EU:EL | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.80 | -0.40% | 200.80 | 199.10 | 204.70 | 202.50 | 199.40 | 202.10 | 437,844 | 16:40:00 |
From May 2019 to May 2024
By Josh Beckerman
Johnson & Johnson (JNJ) said Wednesday that a unique contact lens that quickly adjusts to changing light conditions has received a medical device license in Canada.
Acuvue Oasys with Transitions, a two-week reusable lens, will be commercially available in the first half of 2019. The lens, developed with EssilorLuxottica SA (EL.FR, ELSOY) unit Transitions Optical, received U.S. Food and Drug Administration approval in April.
The lens reduces bright light, filters blue light and blocks ultraviolet rays. On Tuesday, Johnson & Johnson announced favorable data from two new studies of photochromic lenses, citing benefits like improved driving performance.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
November 07, 2018 13:33 ET (18:33 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Essilorluxottica Chart |
1 Month Essilorluxottica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
